This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fombonne, E.
Right arrow Articles by Chakrabarti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fombonne, E.
Right arrow Articles by Chakrabarti, S.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Measles
Yersinia enterocolitica and...

PEDIATRICS Vol. 108 No. 4 October 2001, p. e58

ELECTRONIC ARTICLE:
No Evidence for A New Variant of Measles-Mumps-Rubella-Induced Autism

Received Mar 26, 2001; accepted May 25, 2001.

Eric Fombonne* and Suniti ChakrabartiDagger

From the * Institute of Psychiatry, Department of Child and Adolescent Psychiatry, King's College London, London, United Kingdom; Dagger  Child Development Center, Central Clinic, Stafford, United Kingdom.

Objective.  A link has been postulated between measles-mumps-rubella (MMR) vaccine and a form of autism that is a combination of developmental regression and gastrointestinal symptoms that occur shortly after immunization. This hypothesis has involved 3 separate claims: 1) that there is new phenotype of autism involving regression and gastrointestinal symptoms, 2) that this new variant is responsible for the alleged rise of autism rates, and 3) that this phenotype is associated with biological findings suggestive of the persistence of measles infection. We tested the first of these claims. If this new "autistic enterocolitis" syndrome had some validity, then 1 or several of the following 6 predictions should be supported by empirical data: 1) childhood disintegrative disorder has become more frequent, 2) the mean age of first parental concern for autistic children who are exposed to MMR is closer to the mean immunization age than in children who are not exposed to MMR, 3) regression in the development of children with autism has become more common in MMR-vaccinated children, 4) the age of onset for autistic children with regression clusters around the MMR immunization date and is different from that of autistic children without regression, 5) children with regressive autism have distinct symptom and severity profiles, and 6) regressive autism is associated with gastrointestinal symptoms and/or inflammatory bowel disorder.

Methods.  Three samples were used. Epidemiologic data on 96 children (95 immunized with MMR at a median age of 13.5 months) who were born between 1992 and 1995 and had a pervasive developmental disorder diagnosis as reported in a recent UK survey (post-MMR sample) were compared with data from 2 previous clinical samples (1 pre-MMR [n = 98] and 1 post-MMR [n = 68]) of autistic patients. All patients were assessed with the standardized Autism Diagnostic Interview (ADI), allowing rigorous comparison of age at first parental concerns and rates of regression across samples. Reliability was excellent on ADI scores, age of parental concern, and developmental regression. Furthermore, data on bowel symptoms and disorders were available in the epidemiologic survey from both pediatric and parental sources, and immunization dates were obtained from computerized records.

Results.  The prevalence of childhood disintegrative disorder was 0.6/10 000 (95% confidence interval: 0.02-3.6/10 000); this very low rate is consistent with previous estimates and is not suggestive of an increased frequency of this form of pervasive developmental disorder in samples of children who are immunized with MMR. There was no difference in the mean age at first parental concern between the 2 samples exposed to MMR (19.3 and 19.2 months) and the pre-MMR sample (19.5 months). Thus, MMR immunization was not associated with a shift toward an earlier age for first parental concerns. Similarly, the rate of developmental regression reported in the post-MMR sample (15.6%) was not different from that in the pre-MMR sample (18.4%); therefore, there was no suggestion that regression in the developmental course of autism had increased in frequency since MMR was introduced. In the epidemiologic sample, the subset of autistic children with regression had no other developmental or clinical characteristics, which would have argued for a specific, etiologically distinct phenotype. Parents of autistic children with developmental regression detected the first symptoms at a very similar age (19.8 months) to those of autistic children without regression (19.3 months). Moreover, the mean intervals from MMR immunization to parental recognition of autistic symptoms were comparable in autistic children with or without regression (248 vs 272 days; not significant). In the epidemiologic sample, gastrointestinal symptoms were reported in 18.8% of children. Constipation was the most common symptom (9.4%), and no inflammatory bowel disorder was reported. Furthermore, there was no association between developmental regression and gastrointestinal symptoms (odds ratio: 0.63; 95% confidence interval: 0.06-3.2; not significant), and only 2.1% of the sample experienced both problems, a rate that did not exceed chance expectations.

Conclusions.  No evidence was found to support a distinct syndrome of MMR-induced autism or of "autistic enterocolitis." These results add to the recent accumulation of large-scale epidemiologic studies that all failed to support an association between MMR and autism at population level. When combined, the current findings do not argue for changes in current immunization programs and recommendations.  Key words:  autism, immunization, MMR, regression, epidemiology.




This article has been cited by other articles:


Home page
 AutismHome page
S. T. Schultz, H. S. Klonoff-Cohen, D. L. Wingard, N. A. Akshoomoff, C. A. Macera, and Ming Ji
Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: The results of a parent survey
Autism, May 1, 2008; 12(3): 293 - 307.
[Abstract] [PDF]

Home page
 Arch Gen PsychiatryHome page
R. J. Landa, K. C. Holman, and E. Garrett-Mayer
Social and Communication Development in Toddlers With Early and Later Diagnosis of Autism Spectrum Disorders
Arch Gen Psychiatry, July 1, 2007; 64(7): 853 - 864.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S. Hilton, K. Hunt, and M. Petticrew
MMR: marginalised, misrepresented and rejected? Autism: a focus group study
Arch. Dis. Child., April 1, 2007; 92(4): 322 - 327.
[Abstract] [Full Text] [PDF]

Home page
 AutismHome page
S. Ozonoff, B. J. Williams, and R. Landa
Parental report of the early development of children with regressive autism: The delays-plus-regression phenotype
Autism, December 1, 2005; 9(5): 461 - 486.
[Abstract] [PDF]

Home page
 Br Med BullHome page
M. Fitzpatrick
MMR: risk, choice, chance
Br. Med. Bull., June 1, 2004; 69(1): 143 - 153.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
MMR vaccine - how effective and how safe?
DTB, April 1, 2003; 41(4): 25 - 29.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. Taylor, E. Miller, R. Lingam, N. Andrews, A. Simmons, and J. Stowe
Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study
BMJ, February 16, 2002; 324(7334): 393 - 396.
[Abstract] [Full Text] [PDF]